Clinical trials: HLA Antigens
Complication of Transplanted Liver
Donor Specific HLA Alloantibodies in Liver Transplantation
The aim is to evaluate the impact of donor specific HLA alloantibodies (DSA) on all-cause mortality and re-transplantation, early allograft dysfunction, acute and chronic rejection, fibrosis, vascular, and biliary complications.
- Trial name
- NCT02784080
- Testing
- HLA-alloantibodies exposure
- Where
- 5 sites in Denmark, Finland and 2 more
- Volunteers
- 858 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Pemphigus, Bullous Pemphigoid
Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
Pemphigus is a rare autoimmune life-threatening blistering condition affecting skin and mucous membranes. Pemphigus belongs to a family of polygenic disorders.
- Conditions
- Pemphigus, Bullous Pemphigoid, Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
- Trial name
- NCT05284929
- Testing
- A single blood sample for HLA typing
- Where
- Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sechenov University
Ependymoma
Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod
The purpose of this study is to see if vaccination with HLA-A2 restricted peptides, combined with the immunoadjuvant imiquimod is safe and can induce immune responses in children with recurrent ependymomas.
- Trial name
- NCT01795313
- Testing
- HLA-A2 restricted synthetic tumor antigen, Imiquimod, enzyme-linked immunosorbent assay
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- James Felker
Bone Marrow Failure Syndrome, Thalassemia
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
In this study, the investigators test 2 dose levels of thiotepa (5 mg/kg and 10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG) to determine the minimum…
- Conditions
- Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia
- Trial name
- NCT03513328
- Testing
- Thiotepa--single daily dose, Thiotepa--escalated dose
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Ewing, Soft Tissue Sarcoma
Hematopoietic Stem Cell Transplantation From Human Leukocyte Antigen (HLA) Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas
This is a perspective multicentric study for the treatment of patients aged equal or less than 60 years and submitted to an allogeneic hematopoietic stem cell transplantation from an HLA compatible related or unrelated donor…
- Trial name
- NCT00998361
- Testing
- Allogeneic hemopoietic stem cell transplant
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Type 1 Diabetes Mellitus
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd also known as retogatein compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous…
- Trial name
- DIAGNODE-3 (NCT05018585)
- Testing
- Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU
- Where
- 60 sites in United States, Czechia and 7 more
- Volunteers
- 321 people
- Sponsor
- Diamyd Medical AB
Organ Transplantation
Re-evaluation of Donor-specific Anti-HLA Alloantibodies Immunoassay After Organ Transplantation, From Antigen Level to Epitope Level
Transplantation is the only treatment for end-stage organ dysfunction, with dialysis for the kidney. However, donor / recipient (D / R) tissue incompatibility accounts for the majority of long-term graft losses, through the…
- Trial name
- ACORG-HLA (NCT03861962)
- Testing
- DNA sequencing called "new generation" (or NGS)
- Volunteers
- 20,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Graft Versus Host Disease, Hematologic Neoplasms
Optimizing PTCy Dose and Timing
Background: Stem cell or bone marrow transplants can cure or control blood cancers. Sometimes the donor cells see the recipient's body as foreign. This can cause complications.
- Trial name
- NCT03983850
- Testing
- Busulfan, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Sickle Cell Disease
Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease
This is a Phase II, single arm, multi-center trial. It is designed to estimate the efficacy and toxicity of hematopoietic stem cell transplantation (HSCT) in patients with sickle cell disease (SCD) who have high risk features.
- Trial name
- STRIDE (NCT01565616)
- Testing
- Conditioning Regimen with Bone Marrow Transplant
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- Emory University
Aplastic Anemia
Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia
Rationale: Chemotherapy with fludarabine, cyclophosphamide and anti-thymocyte globulin may induce the engraftment cross the immunologic barrier in the setting of HLA-haploidentical allogeneic hematopoietic cell transplantation.
- Trial name
- NCT01105273
- Testing
- anti-thymocyte globulin, filgrastim, Fludarabine
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Asan Medical Center
Lymphoma, Myeloma
Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions
The purpose of this research study is to examine the safety of infusing escalated doses of allogeneic (from a relative of the patient), enriched natural killer (NK) cells after autologous (from the patient) stem cell…
- Conditions
- Lymphoma, Myeloma, Leukemia
- Trial name
- NCT00660166
- Testing
- NK-Cell Infusion
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Tufts Medical Center
Hematologic Diseases, Leukemia
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
The goal of this clinical research study is to learn if cyclophosphamide given after busulfan and fludarabine can help to prevent graft versus host disease (GVHD - a condition in which transplanted tissue attacks the body into…
- Conditions
- Hematologic Diseases, Leukemia, Lymphoma, Myeloma
- Trial name
- NCT00800839
- Testing
- Busulfan, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- M.D. Anderson Cancer Center
Human Leukocyte Antigens (HLA)
Clinical Protocol SeCore, uTYPE and 3500 Dx System
The purpose of this study is to compare the Invitrogen SeCore(R) sequencing system and uTYPE(R) interpretation software to the predicate device Invitrogen SSP UniTray(R) with UniMatch(R) interpretation software and show 95%…
- Trial name
- NCT01285427
- Volunteers
- 300 people
- Sponsor
- Life Technologies Corporation
Kidney Failure, Chronic
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
The purpose of this study is to determine if IGIV-C, 10% will be effective in converting a donor-recipient crossmatch status from positive to negative.
- Trial name
- NCT00090194
- Testing
- Immune Globulin Intravenous (Human), 10%
- Where
- 16 sites in United States
- Volunteers
- 56 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
BK Virus Infection
Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)
Patients enrolled on this study will have received a stem cell transplant. After a transplant, while the immune system grows back the patient is at risk for infection.
- Trial name
- NCT02313844
- Testing
- Viralym-B
- Where
- 2 sites in United States
- Sponsor
- AlloVir
Alcoholism, HIV Infection
Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi's Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility Antigens
We propose to test, by DNA linkage analysis of family pedigree members, the following interrelated hypotheses: 1) that sexual orientation is genetically influenced; 2) that the development of Kaposi's sarcoma and other outcomes…
- Conditions
- Alcoholism, HIV Infection, Homosexuality, Kaposi's Sarcoma
- Trial name
- NCT00001294
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Graft Versus Host Disease, Leukemia
Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00002790
- Testing
- cyclosporine, methotrexate, sirolimus
- Sponsor
- Fred Hutchinson Cancer Center
Graft-vs-Host Disease
Keratinocyte Growth Factor to Prevent Acute GVHD
This is a study to determine the safety and efficacy of keratinocyte growth factor (KGF) to prevent acute graft-versus-host disease (GVHD) in patients undergoing allogeneic bone marrow (BM) or peripheral blood progenitor cell…
- Trial name
- NCT00031148
- Testing
- Recombinant Human Keratinocyte Growth Factor (rHuKGF)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- FDA Office of Orphan Products Development
Chronic Heart Failure
Human Leucocyte Antigen G and Chronic Heart Failure
The Human leukocyte antigen G (HLA-G) is a non-classical, major histocompatibility complex class I (MHC-I) protein that modulates the immune response, inhibiting it in most cases.
- Trial name
- NCT03655925
- Testing
- plasmatic HLA-G
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Piera Boschetto
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00253552
- Testing
- filgrastim, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- OHSU Knight Cancer Institute